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Abstract Juvenile cystinosis was diagnosed in a patient
who presented with severe headache attacks and photopho-
bia. Treatment with oral cysteamine and topical cysteamine
eye drops was started. One-and-a-half years later, he
developed unilateral gynecomastia and elevated prolactin
and growth hormone levels. A pituitary macroprolactinoma
was discovered and successfully treated with the dopamine
agonist cabergoline. Increased serum growth hormone
levels were attributed to enhanced growth hormone
production by the prolactinoma and somatostatin inhibition
by cysteamine. Although the occurrence of prolactinoma in
this patient could be a simple coincidence, it might also be
a rare yet unrecognised complication of cystinosis.
Keywords Cystinosis . Cysteamine . Prolactinoma .
Growth hormone . Headache
Abbreviations
GH growth hormone
IGF-1 insuline-like growth factor 1
Introduction
Cystinosis is a rare autosomal recessive disorder caused by
mutations of cystinosis gene (CTNS, 17p13.3), encoding
the lysosomal cystine carrier. This results in the intra-
lysosomal accumulation of cystine throughout the body and
intracellular crystal formation. Three clinical forms of
cystinosis varying in severity and age of onset are
distinguished. In the most severe, infantile form (MIM
219800), patients develop renal Fanconi syndrome during
the first year of life and, when untreated with cysteamine,
end-stage renal disease before the age of 10 years. Patients
with the intermediate, juvenile form (MIM 219900)
generally develop symptoms at a later age and have a
slower rate of renal disease progression. As well as renal
disease, patients with cystinosis suffer from extrarenal
complications involving cornea, brain, retina, muscles,
thyroid, pancreas and liver. In the ocular form of cystinosis
(MIM 219750), only the cornea is affected, and other
organs are spared. The incidence of cystinosis is 1:200,000;
the juvenile and ocular forms are seen in less than 5% of all
patients [1]. Treatment with the amino thiol cysteamine
depletes intralysosomal cystine content, decreases the rate
of renal disease progression, improves growth and protects
extrarenal organs [1, 2].
Prolactinomas are functioning pituitary adenomas, which
produce either prolactin, prolactin and growth hormone
(GH) or prolactin and adrenocorticotrophic hormone. Their
occurrence in children is extremely rare [3]. Until now, the
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occurrence of prolactinoma has not been reported in
patients with cystinosis. Here we report a patient with the
association of juvenile cystinosis and prolactinoma with
coproduction of GH.
Case report
A 10-year-old adopted Brazilian boy with congenital
deafness, possibly due to congenital cytomegalovirus
infection, presented with weekly attacks of severe headache
and photophobia. At that time, his height was 133 cm
(−1.5 SD), weight 23.4 kg (−2.5 SD) and blood pressure
110/75 mmHg. Further physical examination, including
neurological examination, was normal. Urine examination
demonstrated proteinuria of 4 g/l without signs of proximal
tubular dysfunction such as aminoaciduria, glucosuria or
phosphaturia. Cerebral computed tomography (CT) was
considered normal.
The diagnosis of juvenile cystinosis was made after
finding corneal cystine crystals on ophthalmologic exami-
nation and elevated cystine levels in both polymorphonu-
clear (PMN) leukocytes and cultured fibroblasts measured
by high-performance liquid chromatography (2.46 and 2.94
1/2 cystine/mg protein respectively). The diagnosis was
later confirmed by mutational analysis of the CTNS gene
(hom 537del21). The patient was subsequently treated with
phosphocysteamine (Laboratory of Pharmaceutical Chem-
istry, University Hospital, Leuven) and topical cysteamine
eye drops. Phosphocysteamine was administered instead of
cysteamine bitartrate (Cystagon®), because the latter drug
was badly tolerated, causing severe gastrointestinal dis-
comfort and an increase in headaches. Cystine levels
measured in PMN on phosphocysteamine (40 mg/kg per
day cysteamine base divided in four doses) were between
0.50 and 1.76 1/2 cystine/mg protein.
At the age of 10.5 years, headaches increased and were
interpreted as migraines, as they were accompanied by
nausea and pain in the eyes. There were no signs of other
neurological disorders, especially not of increased intracra-
nial pressure. Treatment with the calcium channel antago-
nist flunarizine and sumatriptan brought no improvement.
At the age of 11.5 years, the patient developed enlargement
of the left breast. His height was 141 cm (−2 SD) and
weight 28.7 kg (−2 SD), his height velocity had not
increased (Fig. 1). Serum prolactin level was 109,265 mE/
l (normal: 80–420 mE/l), random serum GH 33 mE/
l (normal: <2 mE/l), insulin-like growth factor 1 (IGF-1)
53.5 nmol/l (normal value for age and pubertal stage: 13–
23 nmol/l). Creatinine clearance at that time was 80 ml/min
per 1.73 m2.
CT of the pituitary gland revealed a macroadenoma of
26×14 mm. A thyrotropin-releasing hormone test and oral
glucose tolerance test were performed, both showing an
abnormal rise of GH. Review of cerebral CT performed at
the age of 9 years revealed the presence of pituitary
microadenoma (<10 mm). Treatment with the dopamine
receptor agonist cabergoline was initiated. According to the
treatment protocol of prolactinoma, no cranial surgery was
performed. Analysis of the multiple endocrine neoplasia
type 1 (MEN-1) gene revealed no mutations.
After 2.5 years of cabergoline treatment, IGF-1 levels
were still increased. To distinguish between cosecretion of
GH by pituitary adenoma and an increase of GH levels due
to the somatostatin inhibiting effect of cysteamine, GH
profiles were performed under cysteamine administration
(40 mg/kg per day) and 4 weeks after cysteamine
withdrawal. The treatment with cabergoline was continued
during the test. Under cysteamine treatment, the mean GH
level over 12 h was 24.1 mE/l (normal 6–16 mE/l), whereas
it was 8.4 mE/l after cysteamine withdrawal. Abnormally
high GH peak values (>60 mE/l) were observed both with
and without cysteamine administration after 220 and 520
min, respectively. Baseline GH levels were normal in both
profiles.
On follow-up after 1 year of treatment, the size of the
prolactinoma had decreased to 7–8 mm on cerebral magnetic
resonance imaging (MRI). Control MRI, performed at the
age of 13.5 years, demonstrated no visible prolactinoma. At
that time, the patient no longer complained about headaches.
A bone age test performed at the age of 13 years and
10 months revealed a bone age of 12 years. Frequent
ophthalmologic investigations never showed papillary oede-
ma, and a lumbar puncture confirmed a normal intracranial
pressure (13 cm H2O). A cardiac ultrasound was performed
because of the prolonged use of cabergoline, which might
induce cardiac valve regurgitation [4], and showed no
abnormality. Due to successful treatment with cabergoline,
serum prolactin and IGF-1 levels fell to minimal 929 mE/
l and 17.7 nmol/l, respectively. During the treatment period,
creatinine clearance declined to 33 ml/min per 1.73 m2.
Discussion
This is the first reported case with the association of
cystinosis and prolactinoma. Although central nervous
system disease is a recognised complication in cystinosis,
the occurrence of prolactinoma has not yet been reported.
Cystinotic encephalopathy might present with mental dete-
rioration and motor difficulties (cerebellar ataxia or spastic-
ity) or acute cerebral ischaemia [5]. Pituitary resistance to
thyroid hormone is also described in patients treated with
thyroxin, indicating pituitary dysfunction [6]. Furthermore,
nonabsorptive hydrocephalus and pseudotumuor cerebri are
reported, which might lead to headache [7, 8]. Both latter
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possibilities were excluded in our patient by the absence of
papillary oedema and normal opening pressure on lumbar
puncture. Headache may, however, be the first symptom of
pituitary adenoma [9].
The pathogenesis of prolactinomas remains obscure.
Mostly, these tumuors comprise of a monoclonal population
of cells in which normal mechanisms of growth control are
subverted [3]. About 10% of patients with sporadic
prolactinomas demonstrate mutations in the tumuor-sup-
pressor gene MEN-1 (11q13) [10]. This genetic abnormality
was excluded in our patient. Dysregulation of the hypotha-
lamic–pituitary axis due to cystine accumulation in his
brain region might have played a role in tumour develop-
ment in this patient. A possible causative role of cysteamine
administration can be excluded due to the fact that pituitary
enlargement was already present on the CT prior to
cysteamine administration. Additionally, long-term cyste-
amine administration is known to result in decreased, rather
than increased, prolactin levels [11].
An intriguing dilemma was the origin of his elevated GH
levels. Although growth is mostly severely retarded in
cystinotic patients, random GH and IGF-1 levels appear to
be normal [12]. Treatment with cysteamine is known to
improve growth [2]. This effect of cysteamine might be
explained by cystine depletion in bones and cartilage, but
also by somatostatin inhibition by cysteamine [13, 14].
In children, increased GH levels do not lead to
acromegaly as they do in adults but to an increase in
growth velocity. Strikingly, the growth velocity of our
patient did not increase in spite of elevated GH levels. On
the contrary, his growth curve started to decline at the age
of 12 (Fig. 1). The increased levels of IGF-1 affirm that his
GH levels were indeed elevated and that the GH levels
reported were not based on a measurement error. The
absence of an increased growth velocity despite elevated
GH levels in this patient is puzzling. Growth retardation in
cystinosis is generally more pronounced compared with
other patients with renal disease, possibly due to cystine
Fig. 1 Growth curve, including the start of cysteamine and cabergoline treatment
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accumulation in bones, the presence of metabolic acidosis
and feeding problems [13]. Delayed puberty, commonly
seen in boys with either cystinosis [15] or macroadenoma
[9] and aggravated by elevated prolactin levels, was seen in
this patient but cannot have played a role to this extent at
the age of 13. Although unproven, unresponsiveness of
bones to the elevated levels of GH and/or IGF-1 can be
suggested.
To distinguish between elevated GH due to cysteamine
administration and GH production by prolactinoma, we
measured GH levels for 12 h overnight while the patient
was under cysteamine treatment and 4 weeks after drug
discontinuation. In normal subjects, GH is released during
the night in a pulsatile fashion and declines to baseline
levels below the lower detection limit between peaks. Here
we observed an increased mean GH level over 12 h solely
under cysteamine therapy, supporting the role of cyste-
amine administration in the elevation of serum GH.
However, the abnormally high GH peak values observed
after cysteamine withdrawal argue for elevated GH pro-
duction by the prolactinoma. Another argument for GH
production by the prolactinoma was the parallel decrease of
prolactin and IGF-1 under cabergoline treatment. Thus, the
increased GH levels found in this patient were probably
caused by a combination of enhanced GH production by
the prolactinoma, which was enhanced by cysteamine
therapy.
Although the occurrence of prolactinoma in our patient
could be a simple coincidence, it might also be a rare yet
unrecognized complication of cystinosis.
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